For the Inventor, By the Inventor

Enter assignee name

New York, NY, United States of America

Wyeth

Calculating rank

USPTO Granted Patents = 1,309

% Expired Patents = 68.4

CIPO Patents = 145

EPO Patents = 232

Trademarks = 140

Forward Citations = 13,070

Loading Chart...

Loading Chart...

1,563 inventors (with patents filed for the assignee):

Gary Paul Stack (61 out of 92 patents)

Syed Muzafar Shah (41 out of 94 patents)

Derek Cecil Cole (34 out of 42 patents)

4. Eugene John Trybulski (32 out of 32 patents)

5. Michael G Kelly (31 out of 72 patents)

6. Hassan Mahmoud Elokdah (31 out of 47 patents)

7. Andrew Fensome (30 out of 56 patents)

8. Mark Edward Ruppen (29 out of 59 patents)

9. Michael Sotirios Malamas (29 out of 76 patents)

10. Jay Edward Wrobel (26 out of 96 patents)

11. Puwen Zhang (26 out of 51 patents)

12. Ronald Charles Bernotas (26 out of 28 patents)

13. Amedeo A Failli (26 out of 79 patents)

14. Tianmin Zhu (25 out of 30 patents)

15. Annaliesa Sybil Anderson (24 out of 59 patents)

Core Competencies:

Pneumococcal Polysaccharide

Antineoplastic Combinations

Designer Osteogenic Proteins

Protein Production

Sustained Release

Immunotherapy Regimes

Mutant Toxins

Nutritional Supplements

Recombinant Protein

Cell Culture

Joint Health

Liquid Formulations

1,309 patents: Sort by Forward Citations

1. 12303592 - Formulations for parenteral delivery of compounds and uses thereof (2025-05-20),

2. 12226470 - Pneumococcal dosing regimen (2025-02-18),

3. 12054762 - Methods of protein production using anti-senescence compounds (2024-08-06),

4. 11969474 - Multivalent pneumococcal polysaccharide-protein conjugate composition (2024-04-30),

5. 11535652 - Compositions relating to a mutant clostridium difficile toxin and methods thereof (2022-12-27),

6. 11376315 - Method for controllingpolysaccharide molecular weight using carbon dioxide (2022-07-05),

7. RE48863 - Compositions relating to a mutanttoxin and methods thereof (2021-12-27),

8. RE48862 - Compositions relating to a mutanttoxin and methods thereof (2021-12-27),

9. 11191830 - Process for preparing pneumococcal polysaccharide-protein conjugates (2021-12-07),

10. 11179369 - Sustained release pharmaceutical compositions (2021-11-23),

11. 11167020 - Pneumococcal dosing regimen (2021-11-09),

12. 11103497 - Treatment of imatinib resistant leukemia (2021-08-31),

13. 11077180 - Non-lipidated variants ofORF2086 antigens (2021-08-03),

14. 11008373 - Designer osteogenic proteins (2021-05-18),

15. 10780160 - Process for preparing pneumococcal polysaccharide-protein conjugates (2020-09-22),

Company Overview

Wyeth, headquartered in New York, NY, is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of innovative pharmaceutical compositions. The company specializes in a diverse range of core technology topics, including pneumococcal polysaccharide formulations, antineoplastic combinations, and designer osteogenic proteins. Wyeth is also engaged in advanced research on immunotherapy regimes, mutant toxins, and nutritional supplements, contributing significantly to the healthcare landscape with its commitment to improving patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

1,309 Patents

#12 in New York, NY

#22 in New York

#392 in US

#768 in the World

New York, NY, United States of America

Wyeth

Forward Citations = 13,070

1,563 inventors:

Gary Paul Stack (61 out of 92 patents)

Syed Muzafar Shah (41 out of 94 patents)

Derek Cecil Cole (34 out of 42 patents)

4. Eugene John Trybulski (32 out of 32 patents)

5. Michael G Kelly (31 out of 72 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Wyeth. Retrieved from https://idiyas.com/company/wyeth

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…